Strasbourg, July 12, 2016. Defymed today announced a partnership with JDRF, the leading global organization funding type 1 diabetes (T1D) research. This new investment gives Defymed the opportunity to advance its pre-clinical studies in order to demonstrate the MailPan® immunoprotection properties, safety and function. This is an essential step before beginning the clinical trials on humans.

JDRF will contribute up to $500,000 in funds to finance preclinical studies on the MailPan® bioartificial pancreas.

For more information about this partnership, please refer to our Press release in English